Supplementary Table 1. Demographic profiles of the discovery (HC=5, ALF=40) and validation (HC=25, ALF=230) cohorts

Diagnosis	Discovery cohort (HC=5; ALF=40)			*P*-value	Validation cohort (HC=25; ALF=230)			*P*-value
	Healthy	Survival ALF	Non-survival ALF		Healthy	Survival ALF	Non-survival ALF	
No. of Individual	**n=5**	**n=8**	**n=32**		**n=25**	**n=84**	**n=146**	
Sex	Male=3; Female=2	Male=7; Female=1	Male=15; Female=17		Male=13; Female=12	Male=50; Female=34	Male=92; Female=54	
Age	26 (22–50)	23.5 (19–42)	32 (20–62)	0.5	23 (19–50)	30 (19–59)	31 (20–62)	0.574
Se bilirubin (mg/dL)	0.65 (0.5–1.1)	11.5 (1.4–20)	19.35 (1.4–68.6)	0.001	0.56 (0.5–1.2)	11.35 (3.3–33.76)	14.5 (0.89–53)	0.0014
AST (IU)	23.5 (21–32)	174 (40–585)	1012 (82–9,047)	0.045	22.5 (21–33)	232 (53–9,087)	1,053 (85–5,692)	0.0307
ALT (IU)	31 (30.7–32.5)	379.5 (37–2481)	711.5 (35–7,167)	0.023	30 (30.8–34.67)	293 (29–7,169)	702.5 (95–7,167)	0.0334
GGT	40 (34–46.8)	32 (20–116)	37 (12–130)	0.013	42 (34–48.94)	45 (12–765)	45 (14–1,124)	0.0165
TP	7.5 (6.76–8.21)	5.3 (4.6–6.8)	5.8 (4.5–7.1)	0.032	8 (6.90–9.45)	5.32(3.56–7.95)	5.5 (2.6–8.12)	0.0385
Se albumin (g/dL)	4.5 (4.1–5.25)	2.7 (2.1–3.5)	2.7 (1.5–3.6)	0.042	4.2 (2.39–5.52)	2.88 (1.8–4.45)	2.7 (1.4–8.08)	0.044
INR	0.77 (0.54–0.8)	1.75 (1.15–2.99)	7.5 (2.49–12.9)	0	0.75 (0.56–0.79)	2.73 (1.06–13.0.1)	8.4 (1.07–11.59)	0
Hb (g/dL)	16 (15–18.5)	12.6 (7.1–16.3)	11.1 (53–14.9)	0.0542	15 (13–18)	10.35 (5.345–16.5)	10.7 (5.398–16.367)	0.0556
TLC (cells/micro liter)	7.9 (1.4–20.0)	13.9 (3.7–40.0)	47.5 (46–87)	0.0034	`7 (1.5–19.9)	14 (3.1–42)	50 (41–89)	0.00335
Neutrophil %	65 (47.5–71)	71 (41–80)	78 (55–89)	0.042	66 (47–72)	74 (54.5–91.01)	80 (39–88.9)	0.0335
Platelet count	302 (236–353)	190.5 (11–539)	156 (93–299)	0.045	301 (235–354)	199.9 (3.89–561)	154 (156–628)	0.036
Serum Creatinine (mg/dL)	1.15 (0.93–1.23)	0.705 (0.09–2.19)	1.035 (0.02–4.06)	0.053	1.14 (0.86–1.25)	0.86 (0.23–8.44)	1.099 (0.02–7.23)	0.0543
Arterial lactate (mg/dL)	-	4.03 (3.5–4.8)	6.938 (6.076–10.98)	0.00	-	4.98 (2.087–10.997)	6.899 (6.086–11.987)	0.00
Arterial ammonia (ug/dL)	-	303 (245–398)	521.5 (408–598)	0.00	-	321 (209-399)	498 (406–699)	0.00
Serum phosphate (mEq/L)	-	3.38 (2.45–3.97)	6.98 (6.097–7.997)	0.00	-	3.78 (2.047–4.97)	6.97 (6.076–8.09)	0.00
Cholestrol (mg/dL)	150 (123–175.6)	91 (85–94)	84 (23–148)	0.45	153 (118–168.7)	105 (71–185)	78 (14–158)	0.033
Triglycerides (mg/dL)	82.5 (72–85.1)	95 (87–98.5)	100 (42–102)	0.27	86.5 (71–87.2)	100 (39–258)	104.3 (14–167)	0.159
HDL Cholestrol (mg/dL)	75 (61.5–83)	3 (2–9.7)	14.3 (1.2–27.5)	0.11	77.2 (60–81.3)	7.9 (3.4–49.3)	10.25 (2.1–25)	0.225
LDL Cholestrol (mg/dL)	88 (72.5–91)	23.8 (18.5–26)	25.9 (6.8–64.7)	0.29	85.9 (71.5–87.4)	22.1 (11.3–126.9)	25.6 (5–107)	0.190
VLDL Cholestrol (mg/dL)	22.5 (18–24.5)	24.6 (18–28.34)	32.2 (12.8–69)	0.20	21.2 (19.5–22)	22.3 (7.8–91.2)	31.4 (8.4–108.1)	0.1
INFECTION AT BASELINE	-	0.0%	43.8%	-	-	28.3%	43.9%	-
COMPLICATIONS								
HE-2	-	50.0%	71.9%	-	-	69.8%	61.7%	-
HE-3	-	50.0%	6.3%	-	-	13.2%	14.0%	-
HE-4	-	0.0%	21.9%	-	-	17.0%	25.2%	-
SEPSIS	-	0.0%	71.9%	-	-	17.0%	54.1%	-
MOF	-	0.0%	59.4%	-	-	0.0%	25.23%	-

https://doi.org/10.3350/cmh.2024.0554

Su pplementary Table 1. Continued

Diagnosis	Discovery cohort (HC=5; ALF=40)			*P*-value	Validation cohort (HC=25; ALF=230)			*P*-value
	Healthy	Survival ALF	Non-survival ALF		Healthy	Survival ALF	Non-survival ALF	
No. of Individual	**n=5**	**n=8**	**n=32**		**n=25**	**n=84**	**n=146**	
NECROSIS	-	0.0%	31.3%	-	-	0.0%	28.0%	-
AKI	-	37.5%	6.3%	-	-	34.38%	45.95%	-
KCH	-	1 (1–3)	2 (1–4)	0.57		1 (1–3)	2 (1–4)	0.74
MELD Score	-	25.5 (14–29)	40 (36–41)	0	-	26 (12–54)	40 (37–49)	0.00
ETIOLOY								
VIRAL	-	57.2%		-	-	61.44%		-
DILI	-	42.8%		-	-	38.55%		-

Values are presented as number only or median (interquartile range).
RF, random forest; FC, fold change; POD, probabilty of detection; MELD, model for end-stage liver disease; TP, Total Protein; INR, International Normalized Ratio; Hb, hemoglobin; TLC, Total Leukocyte Count; HDL, High Density Lipoprotein; VLDL, Very Low Density Lipoprotein; MOF, metal organic framework; AKI, acute kidney injury; MELD, model for end-stage liver disease.

http://www.e-cmh.org
https://doi.org/10.3350/cmh.2024.0554